Skip to main content

Table 1 Selected monoclonal antibodies in ALL and AML

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Selected monoclonal antibodies in ALL

Selected monoclonal antibodies in AML

 

Rituximab

anti-CD20 antibody

SGN-CD33A

anti-CD33 pyrrolobenzodiazepine dimer

Ofatumumab

anti-CD20 antibody

AMG 330

anti-CD33 and CD3, bi-specific T cell engager antibody

Epratuzumab

anti-CD22 antibody

MGD006

anti-CD123 and CD3, dual affinity retargeting molecule

Alemtuzumab

anti-CD52 antibody

CSL362

anti-CD123 antibody

Inotuzumab ozogamicin

Monoclonal anti-CD22 immunotoxin

SL-401

diphtheria toxin interleukin-3 fusion protein against CD123

Blinatumomab

bi-specific T cell engager antibody

  

Moxetunomab pasudotox

conjugated immunotoxin targeting CD22

 Â